Industry

* Although Oasis generally supports the separation of business execution and oversight, Oasis is calling on shareholders to vote AGAINST Kobayashi Pharma transitioning to a Company with an Audit and Supervisory Committee, as Oasis believes it may further entrench the founding family’s control over the Company * Oasis continues to urge all shareholders to vote … [Read more…]

– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively – Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend … [Read more…]

Prince’s expertise will advance CHG’s integrated staffing model, pairing immediate locums solutions with long‑term permanent placement strategies MIDVALE, Utah–(BUSINESS WIRE)–CHG Healthcare announces that Ema Prince has been named President of CompHealth’s Permanent Placement Division, reinforcing the company’s enterprise-wide strategy to help healthcare organizations build stable, long‑term clinical workforces in the face of continued physician shortages. … [Read more…]

EL SEGUNDO, Calif.–(BUSINESS WIRE)–Greater Good Health, a premier partner to risk-bearing organizations in managing total cost of care, announced today a $20.5 million Series B financing led by Allumia Ventures, along with up to $12.5 million in a venture debt facility from HSBC Innovation Banking. Participation came from new investors DaVita Venture Group and Granite … [Read more…]

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Pulse Biosciences’ Management is scheduled to present on Wednesday, March 18, 2026, at … [Read more…]

HANGZHOU, China–(BUSINESS WIRE)–Recently, the winners of the prestigious French Design Awards, often referred to as the “pinnacle” of the design world, have been announced. In this award selection, GUTX, a professional probiotic brand produced by Siliankang® under Hangzhou Grand Biologic Pharmaceutical INC won the 2025 French Design Awards for its world-first “Dual-Compartment Fresh Probiotic” packaging … [Read more…]

Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland–(BUSINESS WIRE)–Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant … [Read more…]

NEW YORK–(BUSINESS WIRE)–Allosteric Bioscience, Inc. is utilizing Genetics, Genomics, Systems Biology, Quantum Computing, Advanced Proprietary AI and Proprietary Molecular Technologies for understanding and controlling the Molecular Mechanism of Aging and Longevity with the goal of optimizing the aging process and extending longevity. Aging factors that are being targeted are Lamin A which is critical for … [Read more…]

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– BEDFORD, Mass. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential … [Read more…]

– U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology – – Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New Zealand and dosing of the 10 mg/kg cohort continues in the UK and Canada – – PepGen reiterates guidance for reporting data from the FREEDOM2 … [Read more…]